Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 4, 2003, Pages 682-689

  Kaufmann, J E ^a   Vischer, U M ^a,b  

^a Division of Clinical Biochemistry   (Switzerland)

^b Department of Geriatric Medicine ^*  (Switzerland)

Author keywords

Desmopressin; Endothelium; Vasopressin V2 receptor

Indexed keywords

ARGIPRESSIN[1 DEAMINO]; BLOOD CLOTTING FACTOR 8; HEMOSTATIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

DRUG EFFECT; HEMOSTASIS; HUMAN; METABOLISM; REVIEW; SECRETION; VASCULAR ENDOTHELIUM; VASODILATATION;

DEAMINO ARGININE VASOPRESSIN; ENDOTHELIUM, VASCULAR; FACTOR VIII; HEMOSTASIS; HEMOSTATICS; HUMANS; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION; VON WILLEBRAND FACTOR;

EID: 0142197167     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00190.x     Document Type: Article

References (104)

1. Mannucci PM, Gagnatelli G, d'Alonzo R. Thrombosis: risk factors and diagnostic approaches. In: Stress and Blood Coagulation (Brinkhous, KM, Hinnom, S, eds). Stuttgart: Schattauer Verlag 1972, 105-10.
2. Cash JD, Gader AM, Costa JD. Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-D-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 1974; 27: 363-1.
3. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
4. Vavra I, Machova A, Holecek V, Cort JH, Zaoral M, Sorm F. Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet 1968; i: 948-52.
5. Edwards CR, Kitau MJ, Chard T, Besser GM. Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies. BMJ 1973; 3: 375-8.
6. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-21.
7. Mannucci PM, Ghirardini A. Desmopressin: twenty years after. Thromb Haemost 1997; 78: 958.
8. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
9. Vischer UM, de Moerloose P. von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease. Crit Rev Oncol Hematol 1999; 30: 93-109.
10. Denis CV Molecular and cellular biology of von Willebrand factor. Int J Hematol 2002; 75: 3-8.
11. Nichols TC, Samama CM, Bellinger DA, Roussi J, Reddick RL, Bonneau M, Read MS, Bailliart O, Koch GG, Vaiman M, Sigman JL, Pignaud GA, Brinkhous KN, Griggs TR, Diouet L. Function of von Willebrand factor after crossed bone marrow transplanta tion between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras [see Comments]. Proc Nail Acad Sci USA 1995; 92: 2455-9.
12. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmer man TS. Multimeric composition of factor VHI/von Willebrand factor following administration of DDAVP. Implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982; 59: 1272-8.
13. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Heliums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-61.
14. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experi mental endotoxemia and administration of l-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-8.
15. Vischer UM, Emeis JJ, Bilo HJ, Stehouwer CD, Thomsen C, Rasmussen O, Hermansen K, Wollheim CB, Ingerslev J. von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel deter mination of the vWf propeptide (vWf: Agll). Thromb Haemost 1998; 80: 1002-7.
16. Loesberg C, Gonsalves MD, Zandbergen J, Willems C, van Aken WG, Stel HV, Van Mourik JA, De Groot PG. The effect of calcium on the secretion of factor VHI-related antigen by cultured human endothelial cells. Biochim Biophys Acta 1983; 763: 160-8.
17. Hamilton KK, Sims PJ. Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J Clin Invest 1987; 79: 600-8.
18. Birch KA, Pober JS, Zavoico GB, Means AR, Ewenstein BM. Calcium/calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothelial cells. J Cell Biol 1992; 118: 1501-10.
19. Vischer UM, Wollheim CB. Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. Thromb Hae most 1997; 77: 1182-8.
20. Vischer UM, Lang U, Wollheim CB. Autocrine regulation of endothelial exocytosis. von Willebrand factor release is induced by prostacyclin in cultured endothelial cells. FEBS Lett 1998; 424:211-5.
21. Vischer UM, Wollheim CB. Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis. Blood 1998; 91: 118-27.
22. Hegeman RJ, van den Eijnden-Schrauwen Y, Emeis JJ. Adenosine 3': 5'-cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Wille brand factor from cultured human endothelial cells. Thromb Haemost 1998; 79: 853-8.
23. Vischer UM, Barth H, Wollheim CB. Regulated von Willebrand factor (vWF) secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. Arterioscler Thromb Vase Biol 2000; 20: 883-91.
24. Cohen RJ, Epstein SE, Cohen LS, Dennis LH. Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of beta-adrenergic-receptor stimulation. Lancet 1968; ii: 1264-6.
25. Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest 1976; 57: 1618-25.
26. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357: 333-5.
27. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992; 357: 336-9.
28. Kobrinsky NL, Doyle JJ, Israels ED, Winter JS, Cheang MS, Walker RD, Bishop AJ. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipi dus. Lancet 1985; i: 1293-4.
29. Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN. Hemodynamic and coagulation responses to l-desamino[8-D-arginine] vasopressin in patients with congeni tal nephrogenic diabetes insipidus. N Engl J Med 1988; 318: 881-7.
30. Bichet DG, Razi M, Arthus MF, Lonergan M, Tittley P, Smiley RK, Rock G, Hirsch DJ. Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechan ism. Kidney Int 1989; 36: 859-66.
31. Oksche A, Rosenthal W The molecular basis of nephrogenic diabetes insipidus. J Mol Med 1998; 76: 326-37.
32. Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J din Invest 2000; 106: 107-16.
33. Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 1993; 154: 496-505.
34. Cort JH, Fischman AJ, Dodds WJ, Rand JH, Schwartz IL. New category of vasopressin receptor in the central nervous system. Evidence that this receptor mediates the release of a humoral factor VHI-mobilizing principle. Int J Pept Protein Res 1981; 17: 14-22.
35. Budiansky S. Research fraud: false data confessed. Nature 1983; 301: 101.
36. Elands J, van Woudenberg A, Resink A, de Kloet ER. Vasopressin receptor capacity of human blood peripheral mono-nuclear cells is sex dependent. Brain Behav Immun 1990; 4: 30-8.
37. Bernat A, Hoffmann P, Dumas A, Serradeil-le Gal C, Raufaste D, Herbert JM. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther 1997; 282: 597-602.
38. Moffat EH, Giddings JC, Bloom AL. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br J Haematol 1984; 57: 651-62.
39. Booth F, Allington MJ, Cederholm-Williams SA. An in vitro model for the study of acute release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 71-8.
40. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56: 104-32.
41. Kooistra T, Schrauwen Y, Arts J, Emeis JJ. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 1994; 59: 233-55.
42. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells, modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987; 109: 97-104.
43. Lansink M, Kooistra T. Stimulation of tissue-type plasminogen activator expression by retinoic acid in human endothelial cells requires retinoic acid receptor beta 2 induction. Blood 1996; 88: 531-41.
44. Pepper MS, Rosnoblet C, Di Sanza C, Kruithof EK. Synergistic induction of t-PA by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells. Thromb Haemost 2001; 86: 702-9.
45. Arts J, Lansink M, Grimbergen J, Toet KH, Kooistra T. Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation. Biochem J 1995; 310: 171-6.
46. Kawai Y, Matsumoto Y, Watanabe K, Yamamoto H, Satoh K, Murata M, Handa M, Ikeda Y Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells. Blood 1996; 87: 2314-21.
47. Wall U, Jern S, Tengborn L, Jern C. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood 1998; 91: 529-37.
48. Chandler WL, Levy WC, Stratton JR. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and pheny-lephrine. Circulation 1995; 92: 2984-94.
49. Huber D, Cramer EM, Kaufmann JE, Meda P, Masse JM, Kruithof EK, Vischer UM. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002; 99: 3637-5.
50. Datta YH, Youssoufian H, Marks PW, Ewenstein BM. Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells. Blood 1999; 94: 2696-703.
51. Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997; 139: 245-56.
52. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999; 33: 1431-5.
53. Derkx FH, Man in't Veld AJ, Jones R, Reid JL, Schalekamp MA. DDAVP (l-desamino-8-D-arginine vasopressin): an antagonist of the pressor action of endogenous vasopressin? J Hypertens Suppl 1983; 1: 58-61.
54. Suzuki S, Takeshita A, Imaizumi T, Hirooka Y, Yoshida M, Ando S, Nakamura M. Biphasic forearm vascular responses to intraarterial arginine vasopressin. J Clin Invest 1989; 84: 427-34.
55. van Lieburg AF, Knoers NV, Monnens LA, Smits P. Effects of arginine vasopressin and l-desamino-8-D-arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect. J Hypertens 1995; 13: 1695-700.
56. Hayoz D, Weber R, Pechere A, Burnier M, Brunner HR. Heterogeneous vascular response to vasopressin: radial artery versus forearm blood flow. J Hypertens 1997; 15: 35-41.
57. Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost 2003; 1: 821-8.
58. Busse R, Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 1990; 265: 133-6.
59. Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, Murad F. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl AcadSci USA 1991; 88: 10480-4.
60. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 97-601.
61. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
62. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK Interaction of oestrogen receptor with the regulatorysubunit of phosphatidylinositol-3-OH kinase [In Process Citation]. Nature 2000; 407: 538-1.
63. Ferro A, Queen LR, Priest RM, Xu B, Ritter JM, Poston L, Ward JP. Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro. Br J Pharmacol 1999; 126: 1872-80.
64. Butt E, Bernhardt M, Smolenski A, Kotsonis P, Frohlich LG, Sickmann A, Meyer HE, Lohmann SM, Schmidt HH. Endothe-lial nitric-oxide synthase (Type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J Biol Chem 2000; 275: 5179-87.
65. Boo YC, Sorescu G, Boyd N, Shiojima I, Du Walsh KJ, Jo H. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Serll79 by Akt-independent mechanisms: role of protein kinase A. J Biol Chem 2002; 277: 3388-96.
66. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
67. Wion KL, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-9.
68. Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 1985; 317: 729-30.
69. Stel HV, van der Kwast TH, Veerman EC. Detection of factor VHI/coagulant antigen in human liver tissue. Nature 1983; 303: 530-2.
70. van der Kwast TH, Stel HV, Cristen E, Bertina RM, Veerman EC. Localization of factor VHI-procoagulant antigen: an immuno-histological survey of the human body using monoclonal antibodies. Blood 1986; 67: 222-7.
71. Kadhom N, Wolfrom C, Gautier M, Allain JP, Frommel D. Factor VIII procoagulant antigen in human tissues. Thromb Haemost 1988; 59: 289-94.
72. Montgomery RR, Gill JC. Interactions between von Willebrand factor and Factor VIII. where did they first meet. J Pediatr Hematol Oncol 2000; 22: 269-75.
73. Figueiredo MS, Brownlee GG. cis-acting elements and transcrip tion factors involved in the promoter activity of the human factor VIII gene. J Biol Chem 1995; 270: 11828-38.
74. Kelly RB. Pathways of protein secretion in eukaryotes. Science 1985; 230: 25-32.
75. Do H, Healey JF, Waller EK, Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999; 274: 19587-92.
76. Hollestelle MJ, Thinnes T, Crain K, Stiko A, Kruijt JK, van Berkel TJ, Loskutoff DJ, van Mourik JA. Tissue distribution of factor VIII gene expression in vivo - a closer look. Thromb Haemost 2001; 86: 855-61.
77. Rosenberg JB, Foster PA, Kaufman RJ, Vokac EA, Moussalli M, Kroner PA, Montgomery RR. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest 1998; 101: 613-24.
78. Rosenberg JB, Greengard JS, Montgomery RR. Genetic induc tion of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vase Biol 2000; 20: 2689-95.
79. Irving MG, Roll FJ, Huang S, Bissell DM. Characterization and culture of sinusoidal endothelium from normal rat liver: lipoprotein uptake and collagen phenotype. Gastroenterology 1984; 87: 1233-47.
80. Lenzi R, Alpini G, Liu MH, Rand JH, Tavoloni N. von Willebrand factor antigen is not an accurate marker of rat and guinea pig liver endothelial cells. Liver 1990; 10: 372-9.
81. Gerlach JC, Zeilinger K, Spatkowski G, Hentschel F, Schnoy N, Kolbeck S, Schindler RK, Neuhaus P. Large-scale isolation of sinusoidal endothelial cells from pig and human liver. J Surg Res 2001; 100: 39-45.
82. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vase Biol 2001; 21: 731-8.
83. Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992; 80: 214-21.
84. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-43.
85. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Will ebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93.
86. Vicente V, Estelles A, Laso J, Moraleda JM, Rivera J, Aznar J. Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators. Thromb Res 1993; 70: 117-22.
87. Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 1989; 108: 1283-9.
88. Takeuchi M, Nagura H, Kaneda T. DDAVP and epinephrine-induced changes in the localization of von Willebrand factor antigen in endothelial cells of human oral mucosa. Blood 1988; 72: 850-4.
89. Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000; 96: 3322-8.
90. Datta YH, Ewenstein BM. Regulated secretion in endothelial cells: biology and clinical implications. Thromb Haemost 2001; 86: 1148-55.
91. Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989; 73: 1109-12.
92. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989; 264: 7768-71.
93. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989; 84: 92-9.
94. Dore M, Korthuis RJ, Granger DN, Entman ML, Smith CW P-selectin mediates spontaneous leukocyte rolling in vivo. Blood 1993; 82: 1308-16.
95. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74: 541-54.
96. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995; 92: 7450-4.
97. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, Wagner DD. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413-22.
98. Subramaniam M, Frenette PS, Saffaripour S, Johnson RC, Hynes RO, Wagner DD. Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-12.
99. Subramaniam M, Saffaripour S, Watson SR, Mayadas TN, Hynes RO, Wagner DD. Reduced recruitment of inflammatory cells in a contact hypersensitivity response in P-selectin-deficient mice. J Exp Med 1995; 181: 2277-82.
100. Denis CV, Andre P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 4072-7.
101. Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillaryvenules. Blood 1995; 86: 2760-6.
102. Inaba K, Umeda Y, Yamane Y, Urakami M, Inada M. Charac-terization of human platelet vasopressin receptor and the relation between vasopressin-induced platelet aggregation and vasopressin binding to platelets. Clin Endocrinol (Oxf) 1988; 29: 377-86
103. Yang X, Disa J, Rao AK. Effect of l-desamino-8-D-argininevasopressin (DDAVP) on human platelets. Thromb Res 1990; 59:809-18.
104. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro andin vivo effects of desmopressin on platelet function. Haematologica 1999; 84: 891-6